OBJECTIVES: To describe the survival rate in a cohort of systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH) and to evaluate possible predictors for SSc-PAH in a cohort of SSc patients. METHODS: Thirty patients with SSc-PAH and 150 SSc patients without PAH were included. Survival and survival on therapy were calculated. Clinical features at baseline were correlated to the risk for development of PAH during follow-up. RESULTS: The 1-, 2-, 3-, and 4-year survival rates were 86, 59, 39, and 22%, respectively, from diagnosis of PAH. The hazard ratio for total mortality in the SSc-PAH group was 3.2 [95% confidence interval (CI) 1.8-5.7] compared to SSc without PAH (p < 0.001). Risk factors at baseline for the development of PAH were: limited skin involvement, low diffusing capacity of the lung for carbon monoxide (DL(CO)), high N-terminal pro-brain natriuretic peptide (NTProBNP), increased estimated systolic pulmonary arterial pressure (ESPAP), and the presence of teleangiectases. Severe peripheral vascular disease requiring iloprost treatment during follow-up was associated with an eightfold increased risk of PAH. CONCLUSION: Despite modern treatment and yearly screening by echocardiography, the survival in SSc-PAH is still low in our cohort. The identified risk factors should be assessed to select patients eligible for right heart catheterization (RHC) to make an earlier diagnosis.
OBJECTIVES: To describe the survival rate in a cohort of systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH) and to evaluate possible predictors for SSc-PAH in a cohort of SSc patients. METHODS: Thirty patients with SSc-PAH and 150 SSc patients without PAH were included. Survival and survival on therapy were calculated. Clinical features at baseline were correlated to the risk for development of PAH during follow-up. RESULTS: The 1-, 2-, 3-, and 4-year survival rates were 86, 59, 39, and 22%, respectively, from diagnosis of PAH. The hazard ratio for total mortality in the SSc-PAH group was 3.2 [95% confidence interval (CI) 1.8-5.7] compared to SSc without PAH (p < 0.001). Risk factors at baseline for the development of PAH were: limited skin involvement, low diffusing capacity of the lung for carbon monoxide (DL(CO)), high N-terminal pro-brain natriuretic peptide (NTProBNP), increased estimated systolic pulmonary arterial pressure (ESPAP), and the presence of teleangiectases. Severe peripheral vascular disease requiring iloprost treatment during follow-up was associated with an eightfold increased risk of PAH. CONCLUSION: Despite modern treatment and yearly screening by echocardiography, the survival in SSc-PAH is still low in our cohort. The identified risk factors should be assessed to select patients eligible for right heart catheterization (RHC) to make an earlier diagnosis.
Authors: Ryan J Tedford; James O Mudd; Reda E Girgis; Stephen C Mathai; Ari L Zaiman; Traci Housten-Harris; Danielle Boyce; Benjamin W Kelemen; Anita C Bacher; Ami A Shah; Laura K Hummers; Fredrick M Wigley; Stuart D Russell; Rajeev Saggar; Rajan Saggar; W Lowell Maughan; Paul M Hassoun; David A Kass Journal: Circ Heart Fail Date: 2013-09-01 Impact factor: 8.790
Authors: Jessica Meijs; Anne A Schouffoer; Nina Ajmone Marsan; Theo Stijnen; Hein Putter; Maarten K Ninaber; Tom W J Huizinga; Jeska K de Vries-Bouwstra Journal: RMD Open Date: 2015-12-01
Authors: Marta Colletti; Angela Galardi; Maria De Santis; Giacomo Maria Guidelli; Angela Di Giannatale; Luigi Di Luigi; Cristina Antinozzi Journal: Int J Mol Sci Date: 2019-09-04 Impact factor: 5.923
Authors: Lorinda Chung; Harrison W Farber; Raymond Benza; Dave P Miller; Lori Parsons; Paul M Hassoun; Michael McGoon; Mark R Nicolls; Roham T Zamanian Journal: Chest Date: 2014-12 Impact factor: 9.410